The Cell and Gene Therapy Advisory Committee (CGTAC) was established to highlight the value of cell and gene therapies to patients and the wider UK economy and to promote the UK’s global role in delivering these transformative treatments and the innovative science behind them.
The committee brings together a large proportion of the UK’s regenerative medicine industry, with over 30 UK companies, including biotechs, pharma, service providers and law firms, as well as key organisations including the Cell and Gene Therapy Catapult and Innovate UK as members.
- Promote UK excellence in cell and gene therapies (CGT) both internationally and with UK policymakers
- Build on strong partnerships with ARM, FIRM and commercial meeting organisers such as Phacilitate, and seek opportunities to engage with other coalitions
- Build connections with the regulatory environment, including the MHRA, EMA and FDA
- Highlight the UK’s leading position in CGT by updating the report series published with ARM
- Provide guidance on the UK’s CGT infrastructure by developing a roadmap of groups and initiatives
- Present information on supply chain issues for CGT and how these might be resolved
- Keep CGT central to government policy, by supporting BIA engagement with government and Parliament
- Respond to opportunities to engage with the NHS on access and reimbursement policies for CGT, including the Innovative Medicines Fund and patient registries
- Play a leading role in the continued development of skills and training for CGT, including promotion of relevant qualifications and courses
- Input to the development of measurements and standards for CGT via the MHRA, the National Measurement System, the British Standards Institute and the Standards Coordinating Body